期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

LC/MS/MS法测定比格犬血浆中埃克替尼及其在药动学研究中的应用 被引量：2

Pharmacokinetics of icotinib in Beagle dog studied by using LC/MS/MS method
下载PDF
导出
摘要 目的:建立灵敏、快速的液相色谱-串联质谱(LC/MS/MS)法测定比格犬血浆中埃克替尼,并用于药动学研究。方法:健康比格犬32只,随机分成4组后,静脉(10mg/kg)或灌胃(10,20和40mg/kg)给予埃克替尼。采用LC/MS/MS法测定血药浓度,并计算出药动学参数。结果:测定埃克替尼的线性范围是0.5～10000ng/mL,日内和日间精密度(RSD)均小于10。静脉给药后AUC0-t为(27.3±15.3)μg.mL-1.h。灌胃给药后AUC0-t分别为(7.47±3.30)、(23.5±11.5)、(54.5±24.9)μg.mL-1.h,埃克替尼在犬体内的绝对生物利用度是27.4。结论:该分析方法选择性好、灵敏度高、操作简便,并成功应用于埃克替尼的比格犬药动学研究。 AIM:To develop an LC/MS/MS method for the determination of icotinib in dog plasma and study the pharmacokinetics of icotinib.METHODS:Icotinib was administered to 32 Beagle dogs via intravenous bolus(10 mg/kg) or oral dosing(10,20 or 40 mg/kg) administration after randomly dividing into 4 groups.The concentrations of icotinib in dog plasma were detected by using LC/MS/MS method,and the pharmacokinetic parameters were calculated.RESULTS:The linear calibration curves were obtained in the concentration range of...
作者 关忠民 陈笑艳 钟大放 王印祥
机构地区 沈阳药科大学 中国科学院上海药物研究所 浙江贝达药业
出处 《中国临床药理学与治疗学》 CAS CSCD 2008年第10期1158-1162,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 埃克替尼 药动学 LC/MS/MS法 比格犬 icotinib pharmacokinetics LC/MS/MS Beagle dog
分类号 R969.1 [医药卫生—药理学]
  • 相关文献

参考文献11

  • 1Holly J. Meany,Elizabeth Fox,Cynthia McCully,Chris Tucker,Frank M. Balis.The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates[J].Cancer Chemotherapy and Pharmacology.2008(3)
  • 2Zhang D,Xie GJ,Davis C,et al.International Publica-tion Number[].WO/A.2003
  • 3McKillop D,Partridge EA,Hutchison M,et al.Pharma-cokinetics of gefitinib,an epidermal growthfactor receptor tyrosine kinaseinhibitor,inrat and dog[].Xenobiotica.2004
  • 4Meany HJ,Fox E,McCully C,et al.The plasma and ce-rebrospinal fluid pharmacokinetics of erlotinib and its ac-tive metabolite(OSI-420)after intravenous administra-tion of erlotinibin non-human primates[].Cancer Chemotherapy and Pharmacology.2008
  • 5Wakeling AE,Guy SP,Woodburn JR,et al.ZD1839(Iressa):an orally active inhibitor of epidermal growth factor signaling with po-tential for cancer therapy[].Cancer Research.2002
  • 6Magne,N,Fischel,JL,Dubreuil,A,Formento,P,Poupon,MF,Laurent-Puig,P,Milano,G.Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumor cells on the antiproliferative effect of ZD1839 (“Iressa”)[].British Journal of Cancer.2002
  • 7David P. O’Brien M.D.,Lindsey A. Nelson M.D.,Jodi L. Williams B.S.,Christopher J. Kemp B.S.,Christopher R. Erwin Ph.D. and Brad W. Warner M.D.Selective Inhibition of the Epidermal Growth Factor Receptor Impairs Intestinal Adaptation after Small Bowel Resection[].Journal of Surgical Research.2002
  • 8Pino,MS,Shrader,M,Baker,CH.Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines[].Cancer Research.2006
  • 9Ciardiello F,Tortora G.A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor[].Clinical Cancer Research.2001
  • 10Anderson NG,Ahmad T,Chan K,et al.ZD1839(Iressa), a novel epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression[].International Journal of Cancer.2001

同被引文献15

引证文献2

二级引证文献14

中国临床药理学与治疗学
2008年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部